CoChat

Retracted: Meta-analysis of Randomized Trials of Ivermectin to Treat SARS-CoV-2 Infection

Open access
Hill, Andrew, Garratt, Anna, Levi, Jacob, Falconer, Jonathan, Ellis, Leah, McCann, Kaitlyn, Pilkington, Victoria, Qavi, Ambar, Wang, Junzheng, Wentzel, Hannah · 2021 · Open Forum Infectious Diseases

Published version of a preprint

Cited by 90

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Ivermectin is an antiparasitic drug being investigated for repurposing against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Ivermectin showed in vitro activity against SARS-COV-2, but only at high concentrations. This meta-analysis investigated ivermectin in 23 randomized clinical trials (3349 patients) identified through systematic searches of PUBMED, EMBASE, MedRxiv, and trial registries. The primary meta-analysis was carried out by excluding studies at a high risk of bias. Ivermectin did not show a statistically significant effect on survival (risk ratio [RR], 0.90; 95% CI, 0.57 to 1.42; P = .66) or hospitalizations (RR, 0.63; 95% CI, 0.36 to 1.11; P = .11). Ivermectin displayed a borderline significant effect on duration of hospitalization in comparison with standard of care (mean difference, –1.14 days; 95% CI, –2.27 to –0.00; P = .05). There was no significant effect of ivermectin on time to clinical recovery (mean difference, –0.57 days; 95% CI, –1.31 to 0.17; P = .13) or binary clinical recovery (RR, 1.19; 95% CI, 0.94 to 1.50; P = .15). Currently, the World Health Organization recommends the use of ivermectin only inside clinical trials. A network of large clinical trials is in progress to validate the results seen to date.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ofid/ofab358This paper is marked retracted.

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Research works printed but not linked: 43

  1. RECOVERY Collaborative Group, 2021, Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, Lancet, 397, 1637, 10.1016/S0140-6736(21)00676-0 · DOI · Paper page
  2. WHO Solidarity Trial Consortium, 2021, Repurposed antiviral drugs for Covid-19—interim WHO solidarity trial results, N Engl J Med, 384, 497, 10.1056/NEJMoa2023184 · DOI · Paper page
  3. Mahase, 2021, Covid-19: budesonide shortens recovery time in patients not admitted to hospital, study finds, BMJ, 373, n957, 10.1136/bmj.n957 · doi:10.1136/bmj.n957
  4. Caly, 2020, The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Res, 178, 104787, 10.1016/j.antiviral.2020.104787 · DOI · Paper page
  5. Arshad, 2020, Prioritization of anti-SARS-Cov-2 drug repurposing opportunities based on plasma and target site concentrations derived from their established human pharmacokinetics, Clin Pharmacol Ther, 108, 775, 10.1002/cpt.1909 · DOI
  6. Schmith, 2020, The approved dose of ivermectin alone is not the ideal dose for the treatment of COVID-19, Clin Pharmacol Ther, 108, 762, 10.1002/cpt.1889 · DOI · Paper page
  7. Jermain, 2020, Development of a minimal physiologically-based pharmacokinetic model to simulate lung exposure in humans following oral administration of ivermectin for COVID-19 drug repurposing, J Pharm Sci, 109, 3574, 10.1016/j.xphs.2020.08.024 · DOI
  8. González Canga, 2008, The pharmacokinetics and interactions of ivermectin in humans—a mini-review, AAPS J, 10, 42, 10.1208/s12248-007-9000-9 · DOI · Paper page
  9. Zhang, 2009, Inhibitory effects of ivermectin on nitric oxide and prostaglandin E2 production in LPS-stimulated RAW 264.7 macrophages, Int Immunopharmacol, 9, 354, 10.1016/j.intimp.2008.12.016 · DOI
  10. Ci, 2009, Avermectin exerts anti-inflammatory effect by downregulating the nuclear transcription factor kappa-B and mitogen-activated protein kinase activation pathway, Fundam Clin Pharmacol, 23, 449, 10.1111/j.1472-8206.2009.00684.x · DOI
  11. Zhang, 2008, Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice, Inflamm Res, 57, 524, 10.1007/s00011-008-8007-8 · DOI · Paper page
  12. Ventre, 2017, Topical ivermectin improves allergic skin inflammation, Allergy, 72, 1212, 10.1111/all.13118 · DOI
  13. Yan, 2011, Anti-inflammatory effects of ivermectin in mouse model of allergic asthma, Inflamm Res, 60, 589, 10.1007/s00011-011-0307-8 · DOI
  14. de Melo, 2021, Anti-COVID-19 efficacy of ivermectin in the golden hamster, EMBO Mol Med
  15. Zaidi, 2021, The mechanisms of action of ivermectin against SARS-CoV-2: an evidence-based clinical review article, J Antibot, 10.1038/s41429-021-00430-5 · DOI
  16. Navarro, 2020, Safety of high-dose ivermectin: a systematic review and meta-analysis, J Antimicrob Chemother, 75, 827, 10.1093/jac/dkz524 · DOI
  17. Tzou, 2020, Coronavirus antiviral research database (CoV-RDB): an online database designed to facilitate comparisons between candidate anti-coronavirus compounds, Viruses, 12, 1006, 10.3390/v12091006 · DOI · Paper page
  18. Shakhsi Niaee, Invermectin as an adjunct treatment for hospitalized adult COVID-19 patients: a randomized, multi-center clinical trial, Asian Pac J Trop Med 2021; 14:266–73
  19. Mahmud, Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial, J Int Med Res, 49
  20. Mohan, Ivermectin in mild and moderate COVID-19 (RIVET-COV): a randomized, placebo-controlled trial, 2021. doi:10.21203/rs.3.rs-191648/v1 · DOI
  21. Chaccour, 2021, The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: a pilot, double-blind, placebo-controlled, randomized clinical trial, EClinicalMedicine, 32, 100720, 10.1016/j.eclinm.2020.100720 · DOI · Paper page
  22. Gonzalez, 2021, Efficacy and safety of Ivermectin and Hydroxychloroquine in patients with severe COVID-19, A randomized controlled trial
  23. Shahbaznejad, 2021, Effects of ivermectin in patients With COVID-19: a multicenter, double-blind, randomized, controlled clinical trial, Clin Ther
  24. Podder, 2021, Outcome of ivermectin treated mild to moderate COVID-19 cases: a single-centre, open-label, randomized controlled study, IMC J Med Sci, 14, 11, 10.3329/imcjms.v14i2.52826 · DOI
  25. Shah Bukhari, Efficacy of ivermectin in COVID-19 patients with mild to moderate disease, 10.1101/2021.02.02.21250840 · DOI
  26. Chowdhury, A randomised trial of ivermectin-doxycycline and hydroxychloroquine-azithromycin therapy on COVID19 patients, 2020. doi:
  27. Vallejos, Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial, BMC Infect Dis 2021; 21:635.
  28. López-Medina, 2021, Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: a randomized clinical trial, JAMA, 325, 1426, 10.1001/jama.2021.3071 · DOI · Paper page
  29. Krolewiecki, 2021, Antiviral effect of high-dose ivermectin in adults with COVID-19: a pilot randomised, controlled, open label, multicentre trial, Eclinicalmedicine, 37, 100959, 10.1016/j.eclinm.2021.100959 · DOI
  30. Babalola, 2021, Ivermectin shows clinical benefits in mild to moderate COVID19: a randomised controlled double-blind, dose-response study in Lagos, QJM-Int J Med, 10.1093/qjmed/hcab035 · DOI · Paper page
  31. Galan, 2021, Phase 2 randomized study on chloroquine, hydroxychloroquine or ivermectin in hospitalized patients with severe manifestations of SARS-CoV-2 infection, Pathog Glob Health, 115, 235, 10.1080/20477724.2021.1890887 · DOI
  32. Abd-Elsalam, 2021, Clinical study evaluating the efficacy of ivermectin in COVID-19 treatment: a randomized controlled study, J Med Virol, 93, 5833, 10.1002/jmv.27122 · DOI · Paper page
  33. Ahmed, 2021, A five day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness, Int J Infect Dis, 103, 214, 10.1016/j.ijid.2020.11.191 · DOI · Paper page
  34. Okumuş, 2021, Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients, BMC Infect Dis, 21, 411, 10.1186/s12879-021-06104-9 · DOI
  35. Zeeshan Khan Chachar, 2020, Effectiveness of ivermectin in SARS-CoV-2/COVID-19 patients, Int J Sci, 09, 31
  36. Chahla, Cluster randomised trials - ivermectin repurposing For COVID-19 treatment of outpatients with mild disease in primary health care centers, 2021. doi:10.21203/rs.3.rs-495945/v1 · DOI
  37. Elgazzar, Efficacy and safety of ivermectin for treatment and prophylaxis of COVID-19 pandemic, 2020. doi:10.21203/rs.3.rs-100956/v3 · DOI · Paper page
  38. The Editors of the Lancet Group, 2020, Learning from a retraction, Lancet, 396, 1056, 10.1016/S0140-6736(20)31958-9 · DOI
  39. Day, 2020, Covid-19: experts criticise claim that remdesivir cuts death rates, BMJ, 370, m2839, 10.1136/bmj.m2839 · doi:10.1136/bmj.m2839
  40. Wang, 2016, Ivermectin induces PAK1-mediated cytostatic autophagy in breast cancer, Autophagy, 12, 2498, 10.1080/15548627.2016.1231494 · doi:10.1080/15548627.2016.1231494
  41. Ghazy, 2020, A systematic review and meta-analysis on chloroquine and hydroxychloroquine as monotherapy or combined with azithromycin in COVID-19 treatment, Sci Rep, 10, 22139, 10.1038/s41598-020-77748-x · DOI
  42. Alhumaid, 2020, Efficacy and safety of lopinavir/ritonavir for treatment of COVID-19: a systematic review and meta-analysis, Trop Med Infect Dis, 5, 180, 10.3390/tropicalmed5040180 · DOI
  43. RECOVERY Collaborative Group, 2020, Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, Lancet, 396, 1345, 10.1016/S0140-6736(20)32013-4 · DOI · Paper page

Cited by

See all 90

Metadata

Authors
Hill, A., Garratt, A., Levi, J., Falconer, J., Ellis, L., McCann, K., Pilkington, V., Qavi, A., Wang, J., & Wentzel, H.
Venue
Open Forum Infectious Diseases
Published
2021-07-06
Volume
8
Issue
11
Pages
ofab358-ofab358
ISSN
2328-8957 (ISSN-L)
OpenAlex
W3121596699
Cited by
90
References
8
FWCI
2.97
Type
journal article
Language
en
Status
Retracted
Open access
gold
Funders
Rainwater Charitable Foundation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.